Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (Nasdaq: COGT) is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib, is a selective KIT inhibitor being developed for systemic mastocytosis and gastrointestinal stromal tumors; the company is also advancing… From the company’s description.
In fiscal 2025, Cogent Biosciences, Inc. reported a net loss of $328.94M. Operations used $264.44M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cogent Biosciences, Inc. does
In the company’s own words
Cogent Biosciences, Inc. (Nasdaq: COGT) is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib, is a selective KIT inhibitor being developed for systemic mastocytosis and gastrointestinal stromal tumors; the company is also advancing programs targeting FGFR2/3, mutant ErbB2, PI3Kα, KRAS and JAK2. Its potential customers are patients with these diseases and, if its candidates receive approval, healthcare providers and payors. Cogent is developing an internal commercial organization to support a potential U.S. launch of bezuclastinib. The company’s pipeline includes CGT4859, an FGFR2/3 inhibitor in Phase 1; CGT4255, a mutant ErbB2 inhibitor in Phase 1; and additional clinical and preclinical programs. Cogent licenses worldwide development and commercialization rights for bezuclastinib from Plexxikon and relies on third parties to manufacture its drug candidates. Its website is https://cogentbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1622229
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cogent Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cogent Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cogent Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cogent Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cogent Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”